Literature DB >> 36066734

Unsupervised machine learning identifies predictive progression markers of IPF.

Jeanny Pan1, Johannes Hofmanninger1, Karl-Heinz Nenning1, Florian Prayer2, Sebastian Röhrich2, Nicola Sverzellati3, Venerino Poletti4,5, Sara Tomassetti4, Michael Weber1, Helmut Prosch6, Georg Langs1.   

Abstract

OBJECTIVES: To identify and evaluate predictive lung imaging markers and their pathways of change during progression of idiopathic pulmonary fibrosis (IPF) from sequential data of an IPF cohort. To test if these imaging markers predict outcome.
METHODS: We studied radiological disease progression in 76 patients with IPF, including overall 190 computed tomography (CT) examinations of the chest. An algorithm identified candidates for imaging patterns marking progression by computationally clustering visual CT features. A classification algorithm selected clusters associated with radiological disease progression by testing their value for recognizing the temporal sequence of examinations. This resulted in radiological disease progression signatures, and pathways of lung tissue change accompanying progression observed across the cohort. Finally, we tested if the dynamics of marker patterns predict outcome, and performed an external validation study on a cohort from a different center.
RESULTS: Progression marker patterns were identified and exhibited high stability in a repeatability experiment with 20 random sub-cohorts of the overall cohort. The 4 top-ranked progression markers were consistently selected as most informative for progression across all random sub-cohorts. After spatial image registration, local tracking of lung pattern transitions revealed a network of tissue transition pathways from healthy to a sequence of disease tissues. The progression markers were predictive for outcome, and the model achieved comparable results on a replication cohort.
CONCLUSIONS: Unsupervised learning can identify radiological disease progression markers that predict outcome. Local tracking of pattern transitions reveals pathways of radiological disease progression from healthy lung tissue through a sequence of diseased tissue types. KEY POINTS: • Unsupervised learning can identify radiological disease progression markers that predict outcome in patients with idiopathic pulmonary fibrosis. • Local tracking of pattern transitions reveals pathways of radiological disease progression from healthy lung tissue through a sequence of diseased tissue types. • The progression markers achieved comparable results on a replication cohort.
© 2022. The Author(s).

Entities:  

Keywords:  Idiopathic pulmonary fibrosis; Tomography, X-ray computed; Unsupervised machine learning

Year:  2022        PMID: 36066734     DOI: 10.1007/s00330-022-09101-x

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   7.034


  20 in total

Review 1.  Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history.

Authors:  Giacomo Sgalla; Alice Biffi; Luca Richeldi
Journal:  Respirology       Date:  2015-11-23       Impact factor: 6.424

2.  Fleischner Society: glossary of terms for thoracic imaging.

Authors:  David M Hansell; Alexander A Bankier; Heber MacMahon; Theresa C McLoud; Nestor L Müller; Jacques Remy
Journal:  Radiology       Date:  2008-01-14       Impact factor: 11.105

Review 3.  Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.

Authors:  John Hutchinson; Andrew Fogarty; Richard Hubbard; Tricia McKeever
Journal:  Eur Respir J       Date:  2015-05-14       Impact factor: 16.671

4.  A new fast accurate nonlinear medical image registration program including surface preserving regularization.

Authors:  Audrunas Gruslys; Julio Acosta-Cabronero; Peter J Nestor; Guy B Williams; Richard E Ansorge
Journal:  IEEE Trans Med Imaging       Date:  2014-06-23       Impact factor: 10.048

5.  Cryptogenic fibrosing alveolitis: clinical features and their influence on survival.

Authors:  M Turner-Warwick; B Burrows; A Johnson
Journal:  Thorax       Date:  1980-03       Impact factor: 9.139

Review 6.  Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group.

Authors:  C M Sköld; E Bendstrup; M Myllärniemi; G Gudmundsson; T Sjåheim; O Hilberg; A Altraja; R Kaarteenaho; G Ferrara
Journal:  J Intern Med       Date:  2016-11-13       Impact factor: 8.989

7.  Quantitative computed tomography imaging of interstitial lung diseases.

Authors:  Brian J Bartholmai; Sushravya Raghunath; Ronald A Karwoski; Teng Moua; Srinivasan Rajagopalan; Fabien Maldonado; Paul A Decker; Richard A Robb
Journal:  J Thorac Imaging       Date:  2013-09       Impact factor: 3.000

8.  Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study.

Authors:  Evans R Fernández Pérez; Craig E Daniels; Darrell R Schroeder; Jennifer St Sauver; Thomas E Hartman; Brian J Bartholmai; Eunhee S Yi; Jay H Ryu
Journal:  Chest       Date:  2009-09-11       Impact factor: 9.410

9.  Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT.

Authors:  Simon L F Walsh; Lucio Calandriello; Nicola Sverzellati; Athol U Wells; David M Hansell
Journal:  Thorax       Date:  2015-11-19       Impact factor: 9.139

10.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Jeffrey L Myers; Luca Richeldi; Christopher J Ryerson; David J Lederer; Juergen Behr; Vincent Cottin; Sonye K Danoff; Ferran Morell; Kevin R Flaherty; Athol Wells; Fernando J Martinez; Arata Azuma; Thomas J Bice; Demosthenes Bouros; Kevin K Brown; Harold R Collard; Abhijit Duggal; Liam Galvin; Yoshikazu Inoue; R Gisli Jenkins; Takeshi Johkoh; Ella A Kazerooni; Masanori Kitaichi; Shandra L Knight; George Mansour; Andrew G Nicholson; Sudhakar N J Pipavath; Ivette Buendía-Roldán; Moisés Selman; William D Travis; Simon Walsh; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2018-09-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.